c p pharmaceuticals limited
c p pharmaceuticals limited Company Information
Company Number
00482106
Next Accounts
Dec 2025
Shareholders
wockhardt bio ag
Group Structure
View All
Industry
Manufacture of pharmaceutical preparations
Registered Address
ash road (north), wrexham industrial estate, wrexham, clwyd, LL13 9UF
Website
www.wockhardt.co.ukc p pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of C P PHARMACEUTICALS LIMITED at £216.3m based on a Turnover of £52.2m and 4.15x industry multiple (adjusted for size and gross margin).
c p pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of C P PHARMACEUTICALS LIMITED at £100.3m based on an EBITDA of £5.6m and a 17.97x industry multiple (adjusted for size and gross margin).
c p pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of C P PHARMACEUTICALS LIMITED at £83.2m based on Net Assets of £42.6m and 1.95x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
C P Pharmaceuticals Limited Overview
C P Pharmaceuticals Limited is a live company located in wrexham, LL13 9UF with a Companies House number of 00482106. It operates in the manufacture of pharmaceutical preparations sector, SIC Code 21200. Founded in May 1950, it's largest shareholder is wockhardt bio ag with a 100% stake. C P Pharmaceuticals Limited is a mature, large sized company, Pomanda has estimated its turnover at £52.2m with low growth in recent years.
Upgrade for unlimited company reports & a free credit check
C P Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded C P Pharmaceuticals Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 5 areas for improvement. Company Health Check FAQs
6 Strong
1 Regular
5 Weak
Size
annual sales of £52.2m, make it larger than the average company (£38.3m)
£52.2m - C P Pharmaceuticals Limited
£38.3m - Industry AVG
Growth
3 year (CAGR) sales growth of 2%, show it is growing at a slower rate (4.8%)
2% - C P Pharmaceuticals Limited
4.8% - Industry AVG
Production
with a gross margin of 65.8%, this company has a lower cost of product (31%)
65.8% - C P Pharmaceuticals Limited
31% - Industry AVG
Profitability
an operating margin of 5.2% make it less profitable than the average company (8.8%)
5.2% - C P Pharmaceuticals Limited
8.8% - Industry AVG
Employees
with 337 employees, this is above the industry average (93)
337 - C P Pharmaceuticals Limited
93 - Industry AVG
Pay Structure
on an average salary of £47.8k, the company has a lower pay structure (£65.3k)
£47.8k - C P Pharmaceuticals Limited
£65.3k - Industry AVG
Efficiency
resulting in sales per employee of £154.8k, this is less efficient (£434.4k)
£154.8k - C P Pharmaceuticals Limited
£434.4k - Industry AVG
Debtor Days
it gets paid by customers after 33 days, this is earlier than average (53 days)
33 days - C P Pharmaceuticals Limited
53 days - Industry AVG
Creditor Days
its suppliers are paid after 142 days, this is slower than average (35 days)
142 days - C P Pharmaceuticals Limited
35 days - Industry AVG
Stock Days
it holds stock equivalent to 143 days, this is more than average (116 days)
143 days - C P Pharmaceuticals Limited
116 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (8 weeks)
0 weeks - C P Pharmaceuticals Limited
8 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 47.7%, this is a similar level of debt than the average (44.2%)
47.7% - C P Pharmaceuticals Limited
44.2% - Industry AVG
C P PHARMACEUTICALS LIMITED financials
C P Pharmaceuticals Limited's latest turnover from March 2024 is £52.2 million and the company has net assets of £42.6 million. According to their latest financial statements, C P Pharmaceuticals Limited has 337 employees and maintains cash reserves of £6 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 52,161,000 | 46,999,000 | 79,886,000 | 48,892,000 | 36,602,000 | 36,979,000 | 35,567,000 | 33,403,000 | 58,016,000 | 75,976,000 | 30,750,000 | 29,581,000 | 27,727,000 | 25,070,000 | 36,952,000 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 17,822,000 | 14,496,000 | 15,247,000 | 13,943,000 | 12,429,000 | 16,314,000 | 16,791,000 | 16,455,000 | 11,793,000 | 11,342,000 | 11,536,000 | 11,373,000 | 11,378,000 | 9,721,000 | 16,590,000 |
| Gross Profit | 34,339,000 | 32,503,000 | 64,639,000 | 34,949,000 | 24,173,000 | 20,665,000 | 18,776,000 | 16,948,000 | 46,223,000 | 64,634,000 | 19,214,000 | 18,208,000 | 16,349,000 | 15,349,000 | 20,362,000 |
| Admin Expenses | 31,607,000 | 32,020,000 | 35,638,000 | 29,153,000 | 24,762,000 | 25,538,000 | 67,095,000 | 26,629,000 | 22,114,000 | 18,709,000 | 17,650,000 | 16,654,000 | 15,216,000 | 15,060,000 | 18,241,000 |
| Operating Profit | 2,732,000 | 483,000 | 29,001,000 | 5,796,000 | -589,000 | -4,873,000 | -48,319,000 | -9,681,000 | 24,109,000 | 45,925,000 | 1,564,000 | 1,554,000 | 1,133,000 | 289,000 | 2,121,000 |
| Interest Payable | 150,000 | 69,000 | 54,000 | 65,000 | 209,000 | 102,000 | 154,000 | 108,000 | 1,391,000 | 1,347,000 | 1,356,000 | 65,000 | 86,000 | ||
| Interest Receivable | 110,000 | 252,000 | 85,000 | 4,000 | 1,000 | 1,802,000 | 1,459,000 | 1,245,000 | 1,281,000 | 1,335,000 | 1,358,000 | ||||
| Pre-Tax Profit | 2,692,000 | 666,000 | 29,086,000 | 5,800,000 | -642,000 | -4,938,000 | -48,528,000 | -9,783,000 | 23,955,000 | 45,817,000 | 1,632,000 | 1,452,000 | 1,058,000 | 57,000 | 1,835,000 |
| Tax | -185,000 | -30,000 | -4,260,000 | -1,019,000 | 1,410,000 | 1,392,000 | 8,651,000 | 1,896,000 | -4,395,000 | -9,365,000 | -97,000 | -78,000 | -14,000 | 66,000 | -242,000 |
| Profit After Tax | 2,507,000 | 636,000 | 24,826,000 | 4,781,000 | 768,000 | -3,546,000 | -39,877,000 | -7,887,000 | 19,560,000 | 36,452,000 | 1,535,000 | 1,374,000 | 1,044,000 | 123,000 | 1,593,000 |
| Dividends Paid | |||||||||||||||
| Retained Profit | 2,507,000 | 636,000 | 24,826,000 | 4,781,000 | 768,000 | -3,546,000 | -39,877,000 | -7,887,000 | 19,560,000 | 36,452,000 | 1,535,000 | 1,374,000 | 1,044,000 | 123,000 | 1,593,000 |
| Employee Costs | 16,096,000 | 15,473,000 | 18,126,000 | 15,107,000 | 13,327,000 | 13,620,000 | 12,380,000 | 11,930,000 | 11,178,000 | 10,901,000 | 10,307,000 | 10,000,000 | 8,807,000 | 8,660,000 | 10,166,000 |
| Number Of Employees | 337 | 350 | 417 | 380 | 330 | 341 | 320 | 311 | 299 | 288 | 291 | 282 | 274 | 275 | 270 |
| EBITDA* | 5,581,000 | 3,080,000 | 31,613,000 | 8,192,000 | 904,000 | -3,342,000 | -46,730,000 | -8,205,000 | 25,492,000 | 47,323,000 | 2,931,000 | 2,861,000 | 2,358,000 | 1,431,000 | 3,685,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 27,253,000 | 24,083,000 | 24,270,000 | 22,799,000 | 21,842,000 | 21,092,000 | 19,479,000 | 18,845,000 | 18,363,000 | 15,559,000 | 11,875,000 | 10,805,000 | 10,326,000 | 10,504,000 | 10,354,000 |
| Intangible Assets | 1,726,000 | 2,039,000 | 2,352,000 | 2,666,000 | 2,933,000 | 2,927,000 | 2,452,000 | 1,200,000 | |||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | 5,311,000 | 6,482,000 | 5,800,000 | 7,834,000 | 9,562,000 | 7,756,000 | 7,466,000 | 1,150,000 | 778,000 | ||||||
| Total Fixed Assets | 34,290,000 | 32,604,000 | 32,422,000 | 33,299,000 | 34,337,000 | 31,775,000 | 29,397,000 | 21,195,000 | 19,141,000 | 15,559,000 | 11,875,000 | 10,805,000 | 10,326,000 | 10,504,000 | 10,354,000 |
| Stock & work in progress | 7,007,000 | 7,069,000 | 9,075,000 | 9,344,000 | 8,189,000 | 7,727,000 | 7,332,000 | 12,473,000 | 11,705,000 | 11,666,000 | 11,062,000 | 7,109,000 | 5,712,000 | 9,116,000 | 7,441,000 |
| Trade Debtors | 4,812,000 | 32,537,000 | 5,535,000 | 26,092,000 | 1,397,000 | 1,414,000 | 1,742,000 | 21,036,000 | 21,522,000 | 11,987,000 | 2,805,000 | 3,133,000 | 2,051,000 | 1,888,000 | 2,416,000 |
| Group Debtors | 32,309,000 | 10,502,000 | 14,424,000 | 10,838,000 | 12,387,000 | 6,468,000 | 1,522,000 | 9,166,000 | 5,188,000 | 4,757,000 | 4,997,000 | 1,676,000 | 2,790,000 | ||
| Misc Debtors | 2,942,000 | 4,170,000 | 1,042,000 | 1,819,000 | 609,000 | 1,587,000 | 1,093,000 | 634,000 | 789,000 | 1,827,000 | 3,083,000 | 1,600,000 | 947,000 | ||
| Cash | 6,000 | 591,000 | 16,119,000 | 1,002,000 | 3,000,000 | 3,000,000 | 3,000,000 | 29,354,000 | 29,165,000 | 20,646,000 | 950,000 | ||||
| misc current assets | |||||||||||||||
| total current assets | 47,076,000 | 40,197,000 | 45,401,000 | 36,438,000 | 28,052,000 | 24,798,000 | 25,070,000 | 70,918,000 | 65,007,000 | 54,099,000 | 19,844,000 | 16,826,000 | 15,843,000 | 14,280,000 | 14,544,000 |
| total assets | 81,366,000 | 72,801,000 | 77,823,000 | 69,737,000 | 62,389,000 | 56,573,000 | 54,467,000 | 92,113,000 | 84,148,000 | 69,658,000 | 31,719,000 | 27,631,000 | 26,169,000 | 24,784,000 | 24,898,000 |
| Bank overdraft | 2,217,000 | 23,624,000 | 21,009,000 | 16,890,000 | 16,444,000 | 7,282,000 | 1,173,000 | 6,979,000 | 3,997,000 | ||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 6,972,000 | 3,130,000 | 6,192,000 | 6,134,000 | 5,757,000 | 3,518,000 | 2,083,000 | 4,946,000 | 2,224,000 | 1,758,000 | 2,147,000 | 2,548,000 | 352,000 | 1,209,000 | 1,105,000 |
| Group/Directors Accounts | 11,757,000 | 11,535,000 | 10,859,000 | 10,239,000 | 18,888,000 | 17,792,000 | 12,157,000 | 18,867,000 | 4,096,000 | 2,882,000 | 2,890,000 | 4,824,000 | 225,000 | 3,726,000 | |
| other short term finances | |||||||||||||||
| hp & lease commitments | 10,000 | 22,000 | 17,000 | 49,000 | 52,000 | 31,000 | 30,000 | 28,000 | 4,000 | 14,000 | 15,000 | ||||
| other current liabilities | 17,823,000 | 18,046,000 | 20,047,000 | 11,916,000 | 1,828,000 | 2,255,000 | 2,804,000 | 4,564,000 | 5,219,000 | 11,532,000 | 1,130,000 | 1,365,000 | 1,818,000 | 2,395,000 | 3,027,000 |
| total current liabilities | 38,769,000 | 32,711,000 | 37,098,000 | 51,923,000 | 47,504,000 | 40,472,000 | 33,537,000 | 28,429,000 | 11,570,000 | 16,202,000 | 13,477,000 | 9,910,000 | 9,153,000 | 7,840,000 | 7,873,000 |
| loans | |||||||||||||||
| hp & lease commitments | 10,000 | 38,000 | 54,000 | 103,000 | 60,000 | 91,000 | 121,000 | 3,000 | 7,000 | 21,000 | |||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | 404,000 | 377,000 | 183,000 | 106,000 | 108,000 | 292,000 | 392,000 | 416,000 | |||||||
| total long term liabilities | 10,000 | 890,000 | 1,163,000 | 6,561,000 | 4,143,000 | 3,791,000 | 2,426,000 | 2,668,000 | 4,385,000 | 1,850,000 | 2,953,000 | ||||
| total liabilities | 38,769,000 | 32,711,000 | 37,098,000 | 51,923,000 | 47,514,000 | 41,362,000 | 34,700,000 | 34,990,000 | 15,713,000 | 19,993,000 | 15,903,000 | 12,578,000 | 13,538,000 | 9,690,000 | 10,826,000 |
| net assets | 42,597,000 | 40,090,000 | 40,725,000 | 17,814,000 | 14,875,000 | 15,211,000 | 19,767,000 | 57,123,000 | 68,435,000 | 49,665,000 | 15,816,000 | 15,053,000 | 12,631,000 | 15,094,000 | 14,072,000 |
| total shareholders funds | 42,597,000 | 40,090,000 | 40,725,000 | 17,814,000 | 14,875,000 | 15,211,000 | 19,767,000 | 57,123,000 | 68,435,000 | 49,665,000 | 15,816,000 | 15,053,000 | 12,631,000 | 15,094,000 | 14,072,000 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 2,732,000 | 483,000 | 29,001,000 | 5,796,000 | -589,000 | -4,873,000 | -48,319,000 | -9,681,000 | 24,109,000 | 45,925,000 | 1,564,000 | 1,554,000 | 1,133,000 | 289,000 | 2,121,000 |
| Depreciation | 2,536,000 | 2,284,000 | 2,298,000 | 2,084,000 | 1,493,000 | 1,531,000 | 1,589,000 | 1,476,000 | 1,383,000 | 1,398,000 | 1,367,000 | 1,307,000 | 1,225,000 | 1,142,000 | 1,564,000 |
| Amortisation | 313,000 | 313,000 | 314,000 | 312,000 | |||||||||||
| Tax | -185,000 | -30,000 | -4,260,000 | -1,019,000 | 1,410,000 | 1,392,000 | 8,651,000 | 1,896,000 | -4,395,000 | -9,365,000 | -97,000 | -78,000 | -14,000 | 66,000 | -242,000 |
| Stock | -62,000 | -2,006,000 | -269,000 | 1,155,000 | 462,000 | 395,000 | -5,141,000 | 768,000 | 39,000 | 604,000 | 3,953,000 | 1,397,000 | -3,404,000 | 1,675,000 | 7,441,000 |
| Debtors | 6,355,000 | 13,012,000 | -7,919,000 | 7,501,000 | 4,598,000 | -377,000 | -8,037,000 | 5,326,000 | 3,128,000 | 13,005,000 | -935,000 | -414,000 | 4,967,000 | -989,000 | 6,153,000 |
| Creditors | 3,842,000 | -3,062,000 | 58,000 | 377,000 | 2,239,000 | 1,435,000 | -2,863,000 | 2,722,000 | 466,000 | -389,000 | -401,000 | 2,196,000 | -857,000 | 104,000 | 1,105,000 |
| Accruals and Deferred Income | -223,000 | -2,001,000 | 8,131,000 | 10,088,000 | -427,000 | -549,000 | -1,760,000 | -655,000 | -6,313,000 | 10,402,000 | -235,000 | -453,000 | -577,000 | -632,000 | 3,027,000 |
| Deferred Taxes & Provisions | -404,000 | 27,000 | 194,000 | 77,000 | -2,000 | -184,000 | -100,000 | -24,000 | 416,000 | ||||||
| Cash flow from operations | 2,722,000 | -13,019,000 | 43,730,000 | 8,982,000 | -934,000 | -1,082,000 | -29,928,000 | -10,309,000 | 12,277,000 | 34,439,000 | -822,000 | 3,359,000 | -753,000 | 259,000 | -5,603,000 |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | 222,000 | 676,000 | 620,000 | -8,649,000 | 1,096,000 | 5,635,000 | -6,710,000 | 14,771,000 | 1,214,000 | -8,000 | -1,934,000 | 4,824,000 | -225,000 | -3,501,000 | 3,726,000 |
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | -10,000 | -22,000 | -23,000 | -48,000 | -52,000 | 64,000 | -30,000 | -28,000 | 149,000 | -7,000 | -14,000 | -15,000 | 36,000 | ||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | -40,000 | 183,000 | 85,000 | 4,000 | -53,000 | -65,000 | -209,000 | -102,000 | -154,000 | 1,694,000 | 68,000 | -102,000 | -75,000 | 1,270,000 | 1,272,000 |
| cash flow from financing | 182,000 | -412,000 | -1,220,000 | -10,509,000 | -84,000 | 4,512,000 | -4,450,000 | 11,308,000 | 240,000 | -945,000 | -2,489,000 | 5,763,000 | -3,821,000 | -1,347,000 | 17,513,000 |
| cash and cash equivalents | |||||||||||||||
| cash | -585,000 | -15,528,000 | 15,117,000 | -1,998,000 | -26,354,000 | 189,000 | 8,519,000 | 20,646,000 | -950,000 | 950,000 | |||||
| overdraft | 2,217,000 | -23,624,000 | 2,615,000 | 4,119,000 | 446,000 | 16,444,000 | -7,282,000 | 6,109,000 | -5,806,000 | 2,982,000 | 3,997,000 | ||||
| change in cash | -2,802,000 | -15,528,000 | 38,741,000 | -4,613,000 | -4,119,000 | -446,000 | -42,798,000 | 189,000 | 8,519,000 | 27,928,000 | -6,109,000 | 5,806,000 | -2,982,000 | -4,947,000 | 950,000 |
c p pharmaceuticals limited Credit Report and Business Information
C P Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for c p pharmaceuticals limited by selecting its closest rivals, whether from the MANUFACTURING sector, other large companies, companies in LL13 area or any other competitors across 12 key performance metrics.
c p pharmaceuticals limited Ownership
C P PHARMACEUTICALS LIMITED group structure
C P Pharmaceuticals Limited has no subsidiary companies.
Ultimate parent company
WOCKHARDT LTD
#0043600
WOCKHARDT BIO AG
#0081666
2 parents
C P PHARMACEUTICALS LIMITED
00482106
c p pharmaceuticals limited directors
C P Pharmaceuticals Limited currently has 2 directors. The longest serving directors include Mr Ravindra Limaye (Feb 2019) and Mr Kevin Downey (May 2024).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Ravindra Limaye | 61 years | Feb 2019 | - | Director | |
| Mr Kevin Downey | 58 years | May 2024 | - | Director |
P&L
March 2024turnover
52.2m
+11%
operating profit
2.7m
+466%
gross margin
65.9%
-4.81%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
42.6m
+0.06%
total assets
81.4m
+0.12%
cash
6k
-0.99%
net assets
Total assets minus all liabilities
c p pharmaceuticals limited company details
company number
00482106
Type
Private limited with Share Capital
industry
21200 - Manufacture of pharmaceutical preparations
incorporation date
May 1950
age
75
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
charnwood pharmaceuticals limited (September 1983)
benger laboratories limited (December 1980)
accountant
-
auditor
MENZIES LLP
address
ash road (north), wrexham industrial estate, wrexham, clwyd, LL13 9UF
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
-
c p pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 20 charges/mortgages relating to c p pharmaceuticals limited. Currently there are 6 open charges and 14 have been satisfied in the past.
c p pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for C P PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
c p pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
